NT-501 is an investigational ocular implant that utilizes an encapsulated cell-based delivery system to deliver continuous ciliary neurotrophic factor.

你有没有遇到过这样的人？打喷嚏、弯腰或者稍微用力，鼻血就流个不停，甚至半夜醒来时，枕头上都是血迹。今天咱们要聊的，就是一位鼻出血“达人”的故事。他的鼻出血经历不是几天、几个月，而是整整50余年！频繁的鼻出血，让这位患者多次因重度贫血住院，反复输血十多 ...

Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s ...

The US regulatory agency has pushed the PDUFA date by three months to 18 March 2025 to “allow for more time to review ...

A drug commonly used to treat breast cancer might be able to help people living with hereditary hemorrhagic telangiectasia ...

The following is a summary of “Prevalence and outcomes of cancer and treatment-associated toxicities for patients with Ataxia Telangiectasia,” published in the November 2024 issue of Allergy and ...

Previous work from the team had identified a lead compound that could cross the blood brain barrier and target the DNA damage repair protein ataxia telangiectasia mutated (ATM). 3 The protein ...

Neurotech Pharmaceuticals, Inc., an innovator in sustained drug delivery for chronic retinal diseases, today announced that the U.S. Food and Drug Administration (FDA), has extended the Prescription ...

By Tarun Sai Lomte Arteriovenous malformations, a hallmark of hereditary hemorrhagic telangiectasia, may be driven by ...

GTx-102 is a novel, concentrated oral-mucosal spray of betamethasone intended to improve neurological symptoms of Ataxia-Telangiectasia (A-T), for which there are currently no FDA-approved therapies.

Considering taking supplements to treat macular telangiectasia type 2? Below is a list of common natural remedies used to treat or reduce the symptoms of macular telangiectasia type 2. Follow the ...

Quince Therapeutics (QNCX) “announced the presentation of two posters at the 2024 International Congress for Ataxia Research (ICAR) of data from its prior Phase 3 ...